A detailed history of Crossmark Global Holdings, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 74,641 shares of AMGN stock, worth $19.7 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
74,641
Previous 75,158 0.69%
Holding current value
$19.7 Million
Previous $23.5 Million 2.41%
% of portfolio
0.43%
Previous 0.45%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$309.38 - $337.38 $159,949 - $174,425
-517 Reduced 0.69%
74,641 $24.1 Million
Q2 2024

Jul 29, 2024

SELL
$262.75 - $319.31 $4.83 Million - $5.87 Million
-18,377 Reduced 19.65%
75,158 $23.5 Million
Q1 2024

May 13, 2024

SELL
$268.87 - $324.56 $5.35 Million - $6.45 Million
-19,880 Reduced 17.53%
93,535 $26.6 Million
Q4 2023

Feb 13, 2024

BUY
$255.7 - $288.46 $124,525 - $140,480
487 Added 0.43%
113,415 $32.7 Million
Q3 2023

Nov 08, 2023

BUY
$218.65 - $271.46 $10.2 Million - $12.6 Million
46,426 Added 69.81%
112,928 $30.6 Million
Q2 2023

Jul 31, 2023

SELL
$214.27 - $253.37 $601,455 - $711,209
-2,807 Reduced 4.05%
66,502 $15.7 Million
Q1 2023

May 12, 2023

BUY
$225.79 - $275.2 $366,005 - $446,099
1,621 Added 2.39%
69,309 $16.8 Million
Q4 2022

Jan 19, 2023

BUY
$229.03 - $291.01 $759,921 - $965,571
3,318 Added 5.15%
67,688 $17.8 Million
Q3 2022

Nov 01, 2022

BUY
$224.46 - $253.15 $1.94 Million - $2.18 Million
8,621 Added 15.46%
64,370 $14.5 Million
Q2 2022

Jul 29, 2022

SELL
$230.71 - $256.74 $9.98 Million - $11.1 Million
-43,279 Reduced 43.7%
55,749 $13.6 Million
Q1 2022

May 11, 2022

SELL
$219.27 - $242.57 $142,306 - $157,427
-649 Reduced 0.65%
99,028 $23.9 Million
Q4 2021

Jan 10, 2022

SELL
$198.88 - $227.6 $599,225 - $685,758
-3,013 Reduced 2.93%
99,677 $22.4 Million
Q3 2021

Oct 21, 2021

BUY
$212.27 - $248.7 $15.2 Million - $17.8 Million
71,653 Added 230.86%
102,690 $21.8 Million
Q3 2021

Oct 13, 2021

SELL
$212.27 - $248.7 $15 Million - $17.6 Million
-70,627 Reduced 69.47%
31,037 $2.62 Million
Q2 2021

Jul 21, 2021

BUY
$233.58 - $259.14 $47,883 - $53,123
205 Added 0.2%
101,664 $24.8 Million
Q1 2021

Apr 15, 2021

SELL
$221.91 - $258.6 $745,617 - $868,896
-3,360 Reduced 3.21%
101,459 $25.2 Million
Q4 2020

Jan 14, 2021

BUY
$216.38 - $257.67 $10.6 Million - $12.6 Million
48,907 Added 87.47%
104,819 $24.1 Million
Q3 2020

Oct 08, 2020

BUY
$234.65 - $260.95 $71,098 - $79,067
303 Added 0.54%
55,912 $14.2 Million
Q2 2020

Aug 14, 2020

BUY
$197.81 - $242.74 $619,145 - $759,776
3,130 Added 5.96%
55,609 $13.1 Million
Q1 2020

Apr 28, 2020

BUY
$182.24 - $241.7 $190,076 - $252,093
1,043 Added 2.03%
52,479 $10.6 Million
Q4 2019

Feb 06, 2020

SELL
$189.21 - $243.2 $735,648 - $945,561
-3,888 Reduced 7.03%
51,436 $12.4 Million
Q3 2019

Oct 09, 2019

SELL
$174.11 - $208.62 $1.11 Million - $1.33 Million
-6,353 Reduced 10.3%
55,324 $10.7 Million
Q2 2019

Jul 09, 2019

SELL
$166.7 - $195.41 $296,726 - $347,829
-1,780 Reduced 2.81%
61,677 $11.4 Million
Q1 2019

May 02, 2019

SELL
$180.87 - $203.88 $299,158 - $337,217
-1,654 Reduced 2.54%
63,457 $12.1 Million
Q4 2018

Jan 31, 2019

SELL
$178.4 - $208.25 $858,996 - $1 Million
-4,815 Reduced 6.89%
65,111 $12.7 Million
Q3 2018

Nov 08, 2018

SELL
$185.29 - $208.89 $990,560 - $1.12 Million
-5,346 Reduced 7.1%
69,926 $14.5 Million
Q2 2018

Jul 31, 2018

SELL
$166.05 - $186.51 $8.02 Million - $9.01 Million
-48,315 Reduced 39.09%
75,272 $13.9 Million
Q1 2018

Apr 16, 2018

SELL
$169.43 - $198.0 $1.54 Million - $1.8 Million
-9,084 Reduced 6.85%
123,587 $21.1 Million
Q4 2017

Feb 05, 2018

BUY
$168.79 - $188.59 $899,819 - $1.01 Million
5,331 Added 4.19%
132,671 $23.1 Million
Q3 2016

Oct 25, 2017

BUY
N/A
127,340
127,340 $23.7 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $141B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Crossmark Global Holdings, Inc. Portfolio

Follow Crossmark Global Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.